Johnson & Johnson reported a strong second quarter with sales surpassing $23.7 billion, driven by medical devices which grew over 8% and pharmaceuticals exceeding $15 billion in revenue. The blockbuster Stelara saw a 43% sales decline due to biosimilar competition, but newer drugs Tremfya and cancer therapeutics including Darzalex showed robust growth. The company raised its full-year growth and earnings guidance, and its shares rallied on the positive results. CEO Joaquin Duato highlighted the resilience of the portfolio despite loss of exclusivity challenges.